Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Solar storms have influenced our history – an environmental historian explains how they could also threaten our future - 2Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- 3How to watch 'A Charlie Brown Christmas' for free this weekend
- 4New York to require social media platforms to display mental health warnings
- 5Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- New science points to 4 distinct types of autism
- Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
- Change Your Physical make-up: Compelling Activities for Muscle Building
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz
- Vote in favor of your Number one kind of juice
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- Manual for Famous Beverages 2024
- Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
